Last reviewed · How we verify
Subcutaneous injection of Secukinumab
Subcutaneous injection of Secukinumab is a IL-17A inhibitor (monoclonal antibody) Small molecule drug developed by Peking Union Medical College. It is currently FDA-approved for Moderate to severe plaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis.
Secukinumab is a monoclonal antibody that blocks interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated diseases.
Secukinumab is a monoclonal antibody that blocks interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated diseases. Used for Moderate to severe plaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis.
At a glance
| Generic name | Subcutaneous injection of Secukinumab |
|---|---|
| Sponsor | Peking Union Medical College |
| Drug class | IL-17A inhibitor (monoclonal antibody) |
| Target | IL-17A (Interleukin-17A) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Secukinumab selectively binds to and neutralizes IL-17A, preventing its interaction with IL-17 receptors on immune and tissue cells. This inhibition reduces the recruitment and activation of neutrophils and other inflammatory cells, thereby suppressing the inflammatory cascade underlying autoimmune and inflammatory conditions. By targeting IL-17A specifically, it modulates the Th17 immune response without broadly suppressing the entire immune system.
Approved indications
- Moderate to severe plaque psoriasis
- Psoriatic arthritis
- Ankylosing spondylitis
- Non-radiographic axial spondyloarthritis
Common side effects
- Nasopharyngitis
- Upper respiratory tract infection
- Diarrhea
- Headache
- Injection site reactions
Key clinical trials
- Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients (PHASE4)
- Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy (PHASE3)
- Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission (PHASE3)
- A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis (PHASE3)
- Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy (PHASE3)
- Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS (PHASE4)
- Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers (PHASE1)
- An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Subcutaneous injection of Secukinumab CI brief — competitive landscape report
- Subcutaneous injection of Secukinumab updates RSS · CI watch RSS
- Peking Union Medical College portfolio CI
Frequently asked questions about Subcutaneous injection of Secukinumab
What is Subcutaneous injection of Secukinumab?
How does Subcutaneous injection of Secukinumab work?
What is Subcutaneous injection of Secukinumab used for?
Who makes Subcutaneous injection of Secukinumab?
What drug class is Subcutaneous injection of Secukinumab in?
What development phase is Subcutaneous injection of Secukinumab in?
What are the side effects of Subcutaneous injection of Secukinumab?
What does Subcutaneous injection of Secukinumab target?
Related
- Drug class: All IL-17A inhibitor (monoclonal antibody) drugs
- Target: All drugs targeting IL-17A (Interleukin-17A)
- Manufacturer: Peking Union Medical College — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Moderate to severe plaque psoriasis
- Indication: Drugs for Psoriatic arthritis
- Indication: Drugs for Ankylosing spondylitis
- Compare: Subcutaneous injection of Secukinumab vs similar drugs
- Pricing: Subcutaneous injection of Secukinumab cost, discount & access